Pacira BioSciences (PCRX) Amortization of Deferred Charges (2023 - 2026)

Pacira BioSciences' Amortization of Deferred Charges history runs 4 years deep, the most recent figure standing at $521000.0 for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 39.91% year-over-year to $521000.0 in Q1 2026; TTM through Mar 2026 was $2.5 million, a 26.17% decrease from a year earlier, with the FY2025 full-year figure at $2.8 million, down 11.86% from the prior year.
• Amortization of Deferred Charges was little changed at $521000.0 in Q1 2026 per PCRX's latest filing, from $520000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $1.4 million in Q4 2023 and bottomed at $520000.0 in Q4 2025.
• The 4-year median for Amortization of Deferred Charges is $763000.0 (2024), against an average of $796384.6.
• Biggest YoY gain for Amortization of Deferred Charges was 27.31% in 2025; the steepest drop was 44.56% in 2025.
• Year by year, Amortization of Deferred Charges stood at $1.4 million in 2023, then sank by 34.73% to $938000.0 in 2024, then slumped by 44.56% to $520000.0 in 2025, then increased by 0.19% to $521000.0 in 2026.
• Per Business Quant, the three latest PCRX Amortization of Deferred Charges figures stand at $521000.0 (Q1 2026), $520000.0 (Q4 2025), and $626000.0 (Q3 2025).